Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

MLA

de Baat, Esmée C., et al. “Primary Cardioprotection with Dexrazoxane in Patients with Childhood Cancer Who Are Expected to Receive Anthracyclines: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.” The Lancet Child & Adolescent Health, vol. 6, no. 12, Dec. 2022, pp. 885–94. EBSCOhost, https://doi.org/10.1016/S2352-4642(22)00239-5.

APA

de Baat, E. C., van Dalen, E. C., Mulder, R. L., Hudson, M. M., Ehrhardt, M. J., Engels, F. K., Feijen, E. A. M., Grotenhuis, H. B., Leerink, J. M., Kapusta, L., Kaspers, G. J. L., Merkx, R., Mertens, L., Skinner, R., Tissing, W. J. E., de Vathaire, F., Nathan, P. C., Kremer, L. C. M., Mavinkurve-Groothuis, A. M. C., & Armenian, S. (2022). Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Child & Adolescent Health, 6(12), 885–894. https://doi.org/10.1016/S2352-4642(22)00239-5

Chicago

de Baat, Esmée C, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, et al. 2022. “Primary Cardioprotection with Dexrazoxane in Patients with Childhood Cancer Who Are Expected to Receive Anthracyclines: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.” The Lancet Child & Adolescent Health 6 (12): 885–94. doi:10.1016/S2352-4642(22)00239-5.